Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?
Shi‐Yong Sun
Frontiers of Medicine (2020) Vol. 15, Iss. 2, pp. 221-231
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

A novel polypeptide encoded by the circular RNA ZKSCAN1 suppresses HCC via degradation of mTOR
Runjie Song, Shuoqian Ma, Jiajia Xu, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 71
Augmented ERO1α upon mTORC1 activation induces ferroptosis resistance and tumor progression via upregulation of SLC7A11
Zixi Wang, Huaiyuan Zong, Weiwei Liu, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 16
Long noncoding RNA LINC01234 promotes hepatocellular carcinoma progression through orchestrating aspartate metabolic reprogramming
Muhua Chen, Chunfeng Zhang, Wei Liu, et al.
Molecular Therapy (2022) Vol. 30, Iss. 6, pp. 2354-2369
Open Access | Times Cited: 50
Coordination of inter-organelle communication and lipid fluxes by OSBP-related proteins
Amita Arora, J. Taskinen, Vesa M. Olkkonen
Progress in Lipid Research (2022) Vol. 86, pp. 101146-101146
Closed Access | Times Cited: 44
Exosome-mediated miR-7-5p delivery enhances the anticancer effect of Everolimus via blocking MNK/eIF4E axis in non-small cell lung cancer
Sile Liu, Weiyuan Wang, Yue Ning, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 2
Open Access | Times Cited: 38
eIF4F-mediated Dysregulation of mRNA Translation in Cancer
Mehdi Amiri, Niaz Mahmood, Soroush Tahmasebi, et al.
RNA (2025), pp. rna.080340.124-rna.080340.124
Closed Access
FBXW7 metabolic reprogramming inhibits the development of colon cancer by down-regulating the activity of arginine/mToR pathways
Qing Li, Yan Li, Tong Zhou, et al.
PLoS ONE (2025) Vol. 20, Iss. 1, pp. e0317294-e0317294
Open Access
Synergistic effects of mTOR inhibitors with VEGFR3 inhibitors on the interaction between TSC2-mutated cells and lymphatic endothelial cells
Hanghang Wang, Danjing Hu, Chongsheng Cheng, et al.
Science China Life Sciences (2025)
Closed Access
A Phase I trial to evaluate cisplatin, gemcitabine and the mTOR inhibitor temsirolimus for first-line treatment of participants with transitional cell urothelial cancer, or advanced solid cancer
Simon Pacey, Javier García Corbacho, Richard D. Baird, et al.
Research Square (Research Square) (2025)
Closed Access
Jolkinolide B sensitizes bladder cancer to mTOR inhibitors via dual inhibition of Akt signaling and autophagy
Jun Sang, Lu Gan, Ming-Feng Zou, et al.
Cancer Letters (2021) Vol. 526, pp. 352-362
Closed Access | Times Cited: 31
mTOR Regulation of AGC Kinases: New Twist to an Old Tail
Timothy R. Baffi, Alexandra C. Newton
Molecular Pharmacology (2021) Vol. 101, Iss. 4, pp. 213-218
Open Access | Times Cited: 30
Chemoresistance in breast cancer: PI3K/Akt pathway inhibitors vs the current chemotherapy.
Parham Jabbarzadeh Kaboli, Saber İmani, Masume Jomhori, et al.
American Journal of Cancer Research (2021) Vol. 11, Iss. 10, pp. 5155-5183
Closed Access | Times Cited: 26
LKB1: Can We Target an Hidden Target? Focus on NSCLC
Gloriana Ndembe, Ilenia Intini, Elisa Perin, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 18
Positive regulation of oxidative phosphorylation by nuclear myosin 1 protects cells from metabolic reprogramming and tumorigenesis in mice
Tomáš Venit, Oscar Sapkota, Wael Abdrabou, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 10
The emerging roles of OSBP-related proteins in cancer: Impacts through phosphoinositide metabolism and protein–protein interactions
Vesa M. Olkkonen
Biochemical Pharmacology (2021) Vol. 196, pp. 114455-114455
Closed Access | Times Cited: 20
Comprehensive analysis of the transcriptome‐wide m6A methylome in invasive malignant pleomorphic adenoma
Zhenyuan Han, Biao Yang, Qin Wang, et al.
Cancer Cell International (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 20
GSTP1-mediated S-glutathionylation of Pik3r1 is a redox hub that inhibits osteoclastogenesis through regulating autophagic flux
Xiaoxiao Ji, Jianqiao Hong, Weinan Yang, et al.
Redox Biology (2023) Vol. 61, pp. 102635-102635
Open Access | Times Cited: 8
Pharmacological mTOR-inhibition facilitates clearance of AD-related tau aggregates in the mouse brain
Martina P. Morawe, Fan Liao, Willi Amberg, et al.
European Journal of Pharmacology (2022) Vol. 934, pp. 175301-175301
Open Access | Times Cited: 13
Case report: Sustained complete remission with all-oral MEPED therapy in a patient with Hodgkin’s disease developing resistance to pembrolizumab
Kathrin Reuthner, P. Aubele, Karin Menhart, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together
Y.-C. Liu, Xiuyun Sun, Qianlong Liu, et al.
Journal of the American Chemical Society (2024)
Closed Access | Times Cited: 2
PI3 kinase signaling pathway in hematopoietic cancers: A glance in miRNA's role
Elham Roshandel, Leila Noorazar, Behrouz Farhadihosseinabadi, et al.
Journal of Clinical Laboratory Analysis (2021) Vol. 35, Iss. 4
Open Access | Times Cited: 16
CSNK2B contributes to colorectal cancer cell proliferation by activating the mTOR signaling
Shijun Yu, Qingqing Hu, Kailing Fan, et al.
Journal of Cell Communication and Signaling (2021) Vol. 15, Iss. 3, pp. 383-392
Open Access | Times Cited: 13
Inhibition of the AKT/mTOR pathway negatively regulates PTEN expression via miRNAs
Lin‐Yan Wan, Yanan Wang, Jie Li, et al.
Acta Biochimica et Biophysica Sinica (2022) Vol. 54, Iss. 11, pp. 1637-1647
Open Access | Times Cited: 9
Drug Repurposing by Tumor Tissue Editing
Florian Lüke, Dennis Christoph Harrer, Pan Pantziarka, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 8
Nanomedicines: intervention in inflammatory pathways of cancer
Firoz Anwar, Salma Naqvi, Saiba Shams, et al.
Inflammopharmacology (2023) Vol. 31, Iss. 3, pp. 1199-1221
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top